Methods:
Weight and motivation for performing healthy behaviors were collected at baseline and over time. The motivation questionnaire enabled categorization into two groups: those performing or not performing health behaviors. Four distinct patterns of weight change were determined: losing weight, gaining weight, and two patterns for fluctuating weight. The relationships between these patterns and motivation for weight loss, following a diet, and exercise were examined using logistic regression models.
Results: Of 1182 subjects, more than half were already performing behaviors to lose weight, diet, and exercise at baseline. Among those who were not, 52% (246/474) started taking action to lose weight after baseline, 54% (241/448) started following a diet, and 42% (232/556) started exercising. Weight change patterns were significantly related to performance of healthy behaviors at follow-up (week 36). Compared to the weight gain pattern, those who experienced a continuous weight loss pattern from baseline to week 36 were 2.2 (95% confidence interval 1.49, 3.37) times more likely to perform the healthy behaviors. Baseline behavior and confidence were also predictive of performing healthy behaviors.
Conclusion:
The current work highlights the importance of weight change patterns for performance of diabetes self-care. Tracking weight patterns over time, assessing confidence for performance of healthy behaviors, and being aware of the relationship between weight changes and diabetes self-care
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INTRODUCTION
Type 2 diabetes is primarily a self-managed disease. Self-care behaviors, such as following a healthy diet, being physically active, taking medications as prescribed, and monitoring health (e.g., glucose levels, body weight, blood pressure) [1] , are an important part of achieving optimal outcomes and can have a major impact on the lives of patients, their families, and society [2] . For a person to adhere to self-care activities, he or she must have the knowledge and skill to perform these activities, the confidence (i.e., self-efficacy [3] ) and motivation to do so, and the belief that performance will be beneficial for managing the disease. Determinants of self-care include cultural [4] , psychosocial [5] , physical [6] , and economic [7] aspects. Treatments can also influence behavior through their impact on factors such as glucose control, weight, blood pressure, and hypoglycemia. Experiencing benefits can be encouraging and may lead to increased performance of healthy behaviors, thus continuing the cycle of realized benefits and reinforcing the behaviors. Conversely, drawbacks associated with treatments may deter performance of healthy behaviors.
Continuous reinforcement of healthy behaviors, as well as continued or maintained weight loss, has been shown to increase motivation [8] . Motivational Interviewing (MI) is a directive, person-centered intervention designed to explore ambivalence/resistance to behavior change, support self-efficacy, and activate motivation to perform target behaviors in a nonjudgemental way [9, 10] . interventions [15] . Research has indicated that interventions tailored to the individual's stage of change work better than generic approaches [16] . Moving to the Action stages of RTC for diabetes-specific behaviors has been related to reductions in HbA1c [17] .
Findings from qualitative interviews among people with type 2 diabetes suggest that individual experiences are complex and influenced by cognitive, behavioral, and emotional dimensions that are linked with all aspects of peoples' daily lives [18] . How people feel about their weight has been posited to be an important driver of behavior. A recent empirical study showed that satisfaction with weight was strongly associated with positive behaviors and outcomes [19] . In our previous work, we found that weight loss led to improvements in self-reported weight-related quality of life and satisfaction with health, which are associated with consistent and persistent performance of healthy behaviors [20] . In that study, for simplicity, participants were classified into two groups: \5 or C5 pounds of weight loss [20] . Note, any threshold chosen is not meaningful for all people; what one person perceives as a meaningful change may not be meaningful to another. In addition, different patterns of response may produce the same change over time, but very different experiences. For example, losing 5 pounds and then gaining it back for a net change of zero is a different experience than never having changed weight.
The experience of regaining weight may be more discouraging than maintaining the same weight. The insights gained from our previous study [20] 
METHODS

Data Set
This analysis is based on results from a 104-week, randomized, double-blind, Phase 3 study that assessed the efficacy and safety of canagliflozin 100 and 300 mg versus maximally tolerated doses of glimepiride in subjects with type 2 diabetes inadequately controlled with metformin and background diet and exercise [22, 23] . Canagliflozin (an agent that inhibits sodium glucose co-transporter 2 [SGLT2]) has been shown to significantly reduce HbA1c, body weight, and blood pressure. Canagliflozin has been associated with adverse events (AEs) related to the mechanism of action (e.g., genital mycotic infections, urinary tract infections, and AEs related to volume depletion and osmotic diuresis); however, canagliflozin has been shown to be well tolerated, as these events led to few discontinuations in the clinical trial program [22, 23] . Glimepiride has also been shown to significantly reduce HbA1c; however, it has been associated with weight gain and an increase in hypoglycemia [2] . In this trial, canagliflozin 300 mg demonstrated superiority, and canagliflozin 100 mg demonstrated noninferiority, to glimepiride in HbA1c lowering at 52 weeks [22] ; these effects were maintained at 104 weeks [23] . Both canagliflozin doses were associated with a mean weight loss of 3.6 kg and glimepiride was associated with a mean weight gain of 0.8 kg at week 104 [23] .
Weight, RTC behavior, the effect of weight on quality of life, and self-efficacy for healthy behaviors were measured at baseline and over time. Specifically, body weight was measured at self-esteem, sexual life, public distress, and work, which are measured on a scale from 0 (highest burden) to 100 (lowest burden).
Self-efficacy for healthy behaviors was measured using the Multidimensional Diabetes Questionnaire (MDQ) at baseline and weeks 4, 8, and 36. This instrument captures self-efficacy for the ability to maintain a healthy weight, follow a diet, and resist food temptations [25] . For simplicity, scales were dichotomized above and below the midpoint, where scores above the midpoint indicate a greater degree of self-efficacy. For weight loss and exercise, self-efficacy was measured using only one item each. For diet, two items that related to following a diet and resisting food temptations were combined ([midpoint on both items versus [midpoint on zero or one item). A check box was provided for respondents to indicate whether they were advised not to exercise; we used this to exclude subjects from the exercise behavior outcome analyses.
Weight Change Patterns
Randomized clinical trials often summarize the effect of an intervention on weight using mean This analysis suggested that subjects experienced steady weight gain, steady weight loss, initial weight loss followed by weight gain, or initial weight gain followed by weight loss.
As a result of these findings, we defined the experience of weight change over time using four patterns, as follows:
• Pattern 1: lost any weight from baseline to week 18, and lost any weight from week 18 to 36;
• Pattern 2: lost any weight from baseline to week 18, and gained any weight or did not change weight from week 18 to 36;
• Pattern 3: gained any weight or did not change weight from baseline to week 18, and lost any weight from week 18 to 36;
• Pattern 4: gained any weight or did not change weight from baseline to week 18, and gained any weight or did not change weight from week 18 to 36. Additional details on the derivation of these patterns are provided in Appendix 1 in the supplementary material.
Statistical Methods
The 
RESULTS
Of 1182 subjects with RTC data at baseline and week 36, more than half were taking Action for weight loss, diet, and exercise at baseline, respectively (n = 1174 for exercise; excludes eight who were advised not to exercise). At baseline, 32% of subjects were taking Action for all three behaviors and 16% were not taking Action for any of the three behaviors. Those taking Action for weight loss at baseline were more likely to be male, less likely to be Caucasian, and had higher self-efficacy for all three self-care behaviors. Among those already taking Action for weight loss, 71% were also taking Action for following a diet and 66% were also taking Action for exercise. Those taking Action for diet at baseline were similar, but additionally had a lower average BMI and better health-related quality of life. The greatest difference in BMI was observed between baseline Action and pre-Action for exercise. HbA1c only differed by baseline RTC for diet, but not for weight loss or exercise (Table 1) . For each behavior, the net proportion of subjects in Action increased between baseline and week 36 by about 10% (Table 2) . Relationships between Action and pre-Action at week 36 and demographic, clinical, and patient-reported variables were generally similar to associations observed at baseline.
Among subjects randomized to canagliflozin, 72% were taking Action for weight loss at week 36 versus 65% for glimepiride (P = 0.015).
Among subjects randomized to canagliflozin, 78% were taking Action for diet at week 36 versus 72% for glimepiride (P = 0.051). For exercise, the proportion taking Action at week 36 was not statistically different by treatment assignment (67% and 64%, respectively).
In examining body weight through week 36, it was observed that 40% of subjects compared to 13% and 40% for glimepiride, respectively (P value comparing distributions \0.001).
Regressions
Weight Loss
Weight change pattern was significantly related to taking Action for weight loss at week 36 (Table 3) . Subjects who experienced Patterns 1 and 2 were 2.2 and 1.7 times more likely to take Action for weight loss at week 36, respectively, versus those in the Pattern 4 group. Consistent with previous research [31] , baseline RTC was an important predictor of future behavior (odds ratio [OR] 4.4). Interestingly, self-efficacy was statistically significant even after controlling for baseline RTC. Baseline BMI, race, and weight-related self-esteem were also significantly related to taking Action for weight loss as week 36. The OR for baseline HbA1c was numerically less than 1 (P = 0.052), suggesting
lower HbA1c values may be related to taking Action. Lower weight-related self-esteem was related to taking Action, which may reflect the need for some level of negative impact of weight on self-esteem to necessitate Action.
Diet
Weight change pattern was significantly related to taking Action for diet at week 36 (Table 3 ).
Compared to the Pattern 4 group, those who experienced Pattern 1 were 1.9 times more likely to follow a diet. Baseline RTC was an important predictor of taking Action for diet at week 36 (OR 6.66). Women were 1.4 times more likely to take Action for diet versus men, and smokers were significantly less likely to take Action for diet. Self-efficacy for following a diet and resisting food temptations was related to being in Action for diet at week 36.
Exercise
Subjects who experienced Pattern 1 were 2 times more likely to be taking Action for exercise compared to those who experienced Table 1 continued (Table 3 ). As for the other self-care behaviors, baseline RTC was an important predictor of taking Action; taking Action for exercise at baseline was related to an eight-fold increase for taking Action at week 36. Despite controlling for this relationship, self-efficacy for exercise was a significant predictor of taking Action.
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DISCUSSION
Weight loss is one of the healthy behaviors recommended by the American Diabetes Association for successful type 2 diabetes management [1] , but motivating patients to lose weight and perform other healthy behaviors is challenging. Part of the problem in motivating people to perform healthy behaviors is the lack of a perceivable relationship between these day-to-day activities and events that may occur many years in the future [33] .
In spite of these challenges, some patients do lose weight. While weight loss and weight maintenance among people with type 2 diabetes is infrequent in everyday clinical inhibitors is experienced in the first 12 weeks after initiation of treatment [23] . However, some people continue to lose weight over time, and others are able to maintain a healthy weight long after 12 weeks [23] . For these people, the psychological effect of the initial weight loss may be different than for those who do not continue to lose or maintain weight. In this study, for about 90% of subjects, the first report of action was prior to or concurrent with the first recorded weight loss for all actions explored. Thus, we do not believe that the action typically precedes weight loss, but more frequent measurement would be required to clarify the temporal relationship.
The current work highlights the importance of weight change patterns for performance of diabetes self-care. Because some therapies have been associated with weight gain while others are considered weight neutral, and more recently approved options are associated with weight loss [34] , treatment choice can influence weight change patterns. When a therapy Clinical measures that are important for the management of type 2 diabetes are increasingly being evaluated based on trajectories or patterns [35] [36] [37] . For example, studies by Feldstein et al. have shown that weight loss trajectories after diagnosis of type 2 diabetes are associated with improvements in glycemic and blood pressure control, while higher stable weight and weight gain patterns are associated with poorer glycemic and blood pressure outcomes [35, 36] . Walraven et al. [37] tracked HbA1c trajectories and observed that unfavorable glycemic outcomes were more common among younger patients and among those with higher baseline HbA1c levels and longer duration of diabetes.
Although patterns of change in clinical variables have been examined, our motivation for defining weight change patterns was to more appropriately reflect the experience of people living with type 2 diabetes. In addition to considering weight as a risk factor for future micro-and macrovascular complications, we hope that health care professionals will also performance of these target behaviors [3, 11] . We focused on weight loss and not treatment effect, since our goal was to describe how weight loss might impact future behaviors.
Because the primary mechanism of action of SGLT2 inhibitors is to cause excretion of excess glucose in urine, the glycemic efficacy of canagliflozin is linked to the causal pathway for weight loss. While the results of Phase 3 trials showed overwhelmingly greater weight loss with canagliflozin compared with placebo and active comparators, many individuals in the comparator arms did lose weight during the studies [22, 23, [28] [29] [30] . We acknowledge that one limitation of this study is that the amount of weight change experienced by the people in this sample is not typical in real-world settings; therefore, the patterns of weight over time in a group of people without an intervention could be different.
'Patient-centered care' has become part of the lexicon for the management of diabetes [2] .
The American Diabetes Association/European
Association for the Study of Diabetes guidelines note, ''Ultimately, it is patients who make the final decisions regarding their lifestyle choices and, to some degree, pharmaceutical interventions they use; their implementation occurs in the context of the patients' real lives and relies on the consumption of resources (both public and private) [2] .'' This work provides empirical support for some small, but meaningful, patient-centered actions that practitioners can take today. Specifically, these include tracking weight change patterns over time, assessing self-efficacy for healthy behaviors, and being aware of the relationship between weight changes and diabetes self-care behaviors.
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